News | July 07, 2023
Aster DM Healthcare increases stake in Malabar Institute of Medical Sciences
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
Shareholding of the company in MIMS has increased from 76.01 per cent to 78.37 per cent
Adding 20,000 liters of installed biologics drug substance manufacturing capacity
The 'A+' rating reflects IOL's robust business model, diversified product portfolio
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Pratima takes on the role of Country Speaker in addition to her role as GM and MD of Merck Specialties in India
Takes over the commercialization of Biosimilars Business from Viatris in 70+ countries
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x
The launch of HULIO in the United States is an important milestone for Biocon Biologics
The €70 million investment will allow the large-scale manufacturing of high-purity reagents for quality control and testing for biopharma customers, increasing annual output by several thousand tons
This request for withdrawal of the two dossiers was made after necessary consultations and receiving guidance from EMA
Subscribe To Our Newsletter & Stay Updated
